miR30a inhibits LOX expression and anaplastic thyroid cancer progression

Myriem Boufraqech, Naris Nilubol, Lisa Zhang, Sudheer Kumar Gara, Samira M. Sadowski, Amit Mehta, Mei He, Sean Davis, Jennifer Dreiling, John A III Copland, Robert Christian Smallridge, Martha M. Quezado, Electron Kebebew

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial-mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC.

Original languageEnglish (US)
Pages (from-to)367-377
Number of pages11
JournalCancer Research
Volume75
Issue number2
DOIs
StatePublished - Aug 8 2015

Fingerprint

Protein-Lysine 6-Oxidase
Thyroid Neoplasms
Down-Regulation
Epithelial-Mesenchymal Transition
Mortality
MicroRNAs
Neoplasms
Up-Regulation
Cell Proliferation
Anaplastic Thyroid Carcinoma
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Boufraqech, M., Nilubol, N., Zhang, L., Gara, S. K., Sadowski, S. M., Mehta, A., ... Kebebew, E. (2015). miR30a inhibits LOX expression and anaplastic thyroid cancer progression. Cancer Research, 75(2), 367-377. https://doi.org/10.1158/0008-5472.CAN-14-2304

miR30a inhibits LOX expression and anaplastic thyroid cancer progression. / Boufraqech, Myriem; Nilubol, Naris; Zhang, Lisa; Gara, Sudheer Kumar; Sadowski, Samira M.; Mehta, Amit; He, Mei; Davis, Sean; Dreiling, Jennifer; Copland, John A III; Smallridge, Robert Christian; Quezado, Martha M.; Kebebew, Electron.

In: Cancer Research, Vol. 75, No. 2, 08.08.2015, p. 367-377.

Research output: Contribution to journalArticle

Boufraqech, M, Nilubol, N, Zhang, L, Gara, SK, Sadowski, SM, Mehta, A, He, M, Davis, S, Dreiling, J, Copland, JAIII, Smallridge, RC, Quezado, MM & Kebebew, E 2015, 'miR30a inhibits LOX expression and anaplastic thyroid cancer progression', Cancer Research, vol. 75, no. 2, pp. 367-377. https://doi.org/10.1158/0008-5472.CAN-14-2304
Boufraqech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A et al. miR30a inhibits LOX expression and anaplastic thyroid cancer progression. Cancer Research. 2015 Aug 8;75(2):367-377. https://doi.org/10.1158/0008-5472.CAN-14-2304
Boufraqech, Myriem ; Nilubol, Naris ; Zhang, Lisa ; Gara, Sudheer Kumar ; Sadowski, Samira M. ; Mehta, Amit ; He, Mei ; Davis, Sean ; Dreiling, Jennifer ; Copland, John A III ; Smallridge, Robert Christian ; Quezado, Martha M. ; Kebebew, Electron. / miR30a inhibits LOX expression and anaplastic thyroid cancer progression. In: Cancer Research. 2015 ; Vol. 75, No. 2. pp. 367-377.
@article{8105baf9f6b5423cb58e1001d40c9f19,
title = "miR30a inhibits LOX expression and anaplastic thyroid cancer progression",
abstract = "Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial-mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC.",
author = "Myriem Boufraqech and Naris Nilubol and Lisa Zhang and Gara, {Sudheer Kumar} and Sadowski, {Samira M.} and Amit Mehta and Mei He and Sean Davis and Jennifer Dreiling and Copland, {John A III} and Smallridge, {Robert Christian} and Quezado, {Martha M.} and Electron Kebebew",
year = "2015",
month = "8",
day = "8",
doi = "10.1158/0008-5472.CAN-14-2304",
language = "English (US)",
volume = "75",
pages = "367--377",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - miR30a inhibits LOX expression and anaplastic thyroid cancer progression

AU - Boufraqech, Myriem

AU - Nilubol, Naris

AU - Zhang, Lisa

AU - Gara, Sudheer Kumar

AU - Sadowski, Samira M.

AU - Mehta, Amit

AU - He, Mei

AU - Davis, Sean

AU - Dreiling, Jennifer

AU - Copland, John A III

AU - Smallridge, Robert Christian

AU - Quezado, Martha M.

AU - Kebebew, Electron

PY - 2015/8/8

Y1 - 2015/8/8

N2 - Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial-mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC.

AB - Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial-mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC.

UR - http://www.scopus.com/inward/record.url?scp=84921033725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921033725&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2304

DO - 10.1158/0008-5472.CAN-14-2304

M3 - Article

C2 - 25488748

AN - SCOPUS:84921033725

VL - 75

SP - 367

EP - 377

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 2

ER -